Last updated on August 2019

A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis


Brief description of study

The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adult and adolescent subjects.

Clinical Study Identifier: NCT03706040

Find a site near you

Start Over

Grekin Skin Institute /ID# 210485

Warren, MI United States
2.44miles
  Connect »